GILD Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$74.21
Updated
Gilead Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$73.26 |
52 Week High | US$87.87 |
52 Week Low | US$71.37 |
Beta | 0.20 |
1 Month Change | 2.35% |
3 Month Change | -7.84% |
1 Year Change | -7.80% |
3 Year Change | 11.80% |
5 Year Change | 14.85% |
Change since IPO | 11,476.90% |
Recent News & Updates
Recent updates
Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77
Mar 13Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution
Mar 01Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77
Feb 28We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated
Feb 15Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77
Feb 13Gilead Sciences: Cheap For A Reason
Feb 10Gilead Sciences: The Sky Is Not Falling
Feb 01Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?
Jan 15What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You
Dec 25These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well
Nov 17Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?
Oct 10We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt
Aug 11Here's Why Gilead Sciences (NASDAQ:GILD) Has Caught The Eye Of Investors
Jul 04Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year
Jun 13Shareholder Returns
GILD | US Biotechs | US Market | |
---|---|---|---|
7D | -2.7% | -2.1% | 0.5% |
1Y | -7.8% | 9.7% | 29.0% |
Return vs Industry: GILD underperformed the US Biotechs industry which returned 9.7% over the past year.
Return vs Market: GILD underperformed the US Market which returned 29% over the past year.
Price Volatility
GILD volatility | |
---|---|
GILD Average Weekly Movement | 4.0% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GILD has not had significant price volatility in the past 3 months.
Volatility Over Time: GILD's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 18,000 | Dan O'Day | https://www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
GILD fundamental statistics | |
---|---|
Market cap | US$91.27b |
Earnings (TTM) | US$5.67b |
Revenue (TTM) | US$27.12b |
16.1x
P/E Ratio3.4x
P/S RatioIs GILD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GILD income statement (TTM) | |
---|---|
Revenue | US$27.12b |
Cost of Revenue | US$5.97b |
Gross Profit | US$21.14b |
Other Expenses | US$15.48b |
Earnings | US$5.67b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 4.55 |
Gross Margin | 77.97% |
Net Profit Margin | 20.89% |
Debt/Equity Ratio | 109.8% |
How did GILD perform over the long term?
See historical performance and comparison